Vitamin D supplements and prevention of cancer and cardiovascular disease

Abstract

This paper describes a large randomized, placebo-controlled trial of vitamin D3 (cholecalciferol) 2000 IU per day in 25,871 US adults. After median follow-up of 5.3 years, supplementation with vitamin D did not alter the risk of the primary end points, invasive cancer of any type hazard ratio, 0.96; 95% confidence interval [CI], 0.88–1.06; P=0.47) or major cardiovascular events (hazard ratio, 0.97; 95% CI, 0.85–1.12; P=0.69).